

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版年	出版名	ページ
坂 英雄, 沖昌英	気管支鏡による小細胞肺癌の診断と治療		コンセンサス 癌治療	ヘルス出版	東京	2012 年	16-20
北川智余恵, 坂 英雄.	8, Pharmacogenomics と pharmacogenetics 2. Irinotecan の 副作用		抗がん薬の臨 床薬理	南山堂	東京	2013 年	102-9
北川智余恵, 中畑征史, 坂 英雄.	3. 神経毒性		オンコロジー クリニカルガ イド肺癌化学 療法	南山堂	東京	2014 年	380-4
北川智余恵, 伊勢裕子, 坂 英雄.	IV 基礎研究 副作用予測のためのバ イオマーカー.		抗がん剤の副 作用と支持療 法-より適切な 抗がん剤の安 全使用をめざ して-	日本臨床	東京	2015 年	114-9

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Akira Ono, Tateaki Naito, Ichiro Ito, Reiko Watanabe, Takehito Shukuya, Hirotsugu Kenmotsu, Asuka Tsuya, Yukiko Nakamura, Haruyasu Murakami, Kyoichi Kaira, <u>Toshiaki</u> <u>Takahashi</u> , Toru Kameya, Takashi Nakajima, Masahiro	Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer	Lung Cancer	76(3)	439-444	2012

<p>Endo, <u>Nobuyuki</u> Yamamoto</p>					
<p>Tateaki Naito, Fumihiro Tanaka, Akira Ono, Kazue Yoneda, <u>Toshiaki</u> <u>Takahashi</u>, Haruyasu Murakami, Yukiko Nakamura, Asuka Tsuya, Hirotsugu Kenmotsu, Takehito Shukuya, Kyoichi Kaira,</p>	<p>Prognostic impact of circulating tumor cells in patients with small-cell lung cancer</p>	<p>Journal of Thoracic Oncology</p>	<p>7(3)</p>	<p>512-519</p>	<p>2012</p>

Yasuhiro Koh, Masahiro Endo, Seiki Hasegawa, <u>Nobuyuki</u> Yamamoto					
Toyokawa G, Taguchi K, Ohba T, Morodomi Y, Takenaka T, Hirai F, Yamaguchi M, <u>Seto T</u> , Takenoyama M, Sugio K, Ichinose Y	First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component	J Thorac Oncol	7(12)	e39-41	2012
Ono A, Naito T, Ito I, Watanabe R, Shukuya T, Kenmotsu H, Tsuya A, Nakamura Y, Murakami H, Kaira K,	Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer.	Lung Cancer.	76(3)	439-444	2012

<p><u>Takahashi T</u>, Kameya T, Nakajima T, Endo M, <u>Yamamoto N</u>.</p>					
<p>Shukuya T, <u>Takahashi T</u>, <u>Harada H</u>, Ono A, <u>Akamatsu</u> <u>H</u>, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Takahashi K, <u>Yamamoto N</u>.</p>	<p>Chemoradiotherapy for limited-disease small-cell lung cancer in elderly patients aged 75 years or older.</p>	<p>Jpn J Clin Oncol</p>	<p>43(2)</p>	<p>176-183</p>	<p>2013</p>
<p>Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsuo K, <u>Saka H</u>, Kurata T, Nishimura Y,</p>	<p>A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903)</p>	<p>Cancer</p>	<p>15</p>	<p>6126-35</p>	<p>2012</p>

Fukuoka M.					
Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, <u>Nishio M</u> , Nogami N, Okamoto H, <u>Saka H</u> , <u>Yamamoto N</u> , Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T.	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.	Invest New Drugs.	31(5)	1395-6	2013

<p>Horinouchi H, Sekine I, Sumi M, Ito Y, <u>Nokihara H</u>, <u>Yamamoto N</u>, Ohe Y, Tamura T.</p>	<p>Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor.</p>	<p>Cancer Sci.</p>	<p>103(4)</p>	<p>756-9</p>	<p>2012</p>
<p><u>Oizumi S</u>, Kobayashi K, <u>Inoue A</u>, Maemondo M, Sugawara S, Yoshizawa H, Isobe H, Harada M, Kinoshita I, Oinaga S, Kato T, Harada T, Gemma A, Saijo Y, Yokomizo Y, Morita S, Hagiwara K, Nukiwa T.</p>	<p>Quality of life with gefitinib in patients with <i>EGFR</i>-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.</p>	<p>Oncologist</p>	<p>17(6)</p>	<p>863-70</p>	<p>2012</p>

<p>Maemondo M, Minegishi Y, <u>Inoue A</u>, Kobayashi K, Harada M, Okinaga S, Morikawa N, <u>Oizumi S</u>, Tanaka T, Isobe H, Kudo S, Hagiwara K, Nukiwa T, Gemma A.</p>	<p>First-line gefitinib in patients aged 75 or more with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations; NEJ 003 study.</p>	<p>J Thorac Oncol</p>	<p>7(9)</p>	<p>1417-22</p>	<p>2012</p>
<p>Morita S, <u>Oizumi S</u>, Minami H, Kitagawa K, Komatsu Y, Fujiwara Y, Inada M, Yuki S, Kiyota N, Mitsuma A, Sawaki M, Tanii H, Kimura J, Ando Y</p>	<p>Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors.</p>	<p>Invest New Drugs 30(5):1950-7, 2012</p>	<p>30(5)</p>	<p>1950-7.</p>	<p>2012</p>

Takehi to Shukuya, <u>Toshiaki</u> <u>Takahashi</u> , <u>Hideyuki</u> Harada, Akira Ono, <u>Hiroaki</u> <u>Akamatsu</u> , Tetsuhiko Taira, Hirotsugu Kenmotsu, Tateaki Naito, Haruyasu Murakami, Masahiro Endo, Kazuhisa Takahashi, _ <u>Nobuyuki</u> <u>Yamamoto</u>	Chemoradiotherapy for Limited-disease Small-cell Lung Cancer in Elderly Patients Aged 75 Years or Older	Japanese Journal of Clinical Oncology	43(2)	176-183	2013
---	--	--	-------	---------	------

Reiko Watanabe, Ichiro Ito, Hirotsugu Kenmotsu, Masahiro Endo, <u>Nobuyuki</u> <u>Yamamoto</u> , Yasuhisa Ohde, Haruhiko Kondo, Takashi Nakajima, Toru Kameya	Large cell neuroendocrine carcinoma of the lung: Is it possible to diagnose from biopsy specimens?	Japanese Journal of Clinical Oncology	43(3)	294-304	2013
Masahito Hosokawa, Takayuki Yoshikawa, Ryo Negishi, Tomoko Yoshino, Yasuhiro Koh, Hirotsugu Kenmotsu, Tateaki Naito,	Microcavity Array System for Size-Based Enrichment of Circulating Tumor Cells from the Blood of Patients with Small-Cell Lung Cancer.	Analytical Chemistry	85(12)	5692-5698	2013

<p><u>Toshiaki Takahashi</u>, <u>Nobuyuki Yamamoto</u>, Yoshihito Kikuhara, Hisashige Kanbara, Tsuyoshi Tanaka, Ken Yamaguchi, Tadashi Matsunaga</p>					
<p>Masahito Hosokawa, Hirotsugu Kenmotsu, Yasuhiro Koh, Tomoko Yoshino, Tsuyoshi Tanaka, Takayuki Yoshikawa, Tateaki Naito, Toshiaki Takahashi, Haruyasu</p>	<p>Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system</p>	<p>PLoS One</p>	<p>8(6)</p>	<p>e67466</p>	<p>2013</p>

<p>Murakami, Yukiko Nakamura, Asuka Tsuya, Takehito Shukuya, Akira Ono, Hiroaki Akamatsu, Reiko Watanabe, Sachiyo Ono, Hisashige Kanbara, Ken Yamaguchi, Tadashi Matsunaga, <u>Nobuyuki</u> <u>Yamamoto</u></p>					
<p>Toyokawa G, Takenoyama M, Taguchi K, Toyozaawa R, Inamasu E, Kojo M, Shiraishi Y, Morodomi Y, Takenaka T, Hirai F,</p>	<p>An extremely rare case of small-cell lung cancer harboring variant 2 of the EML4-ALK fusion gene</p>	<p>Lung Cancer</p>	<p>81(3)</p>	<p>487-490</p>	<p>2013</p>

Yamaguchi M, <u>Seto T</u> , Shimokawa M, Ichinose Y					
Toyokawa G, Toyzawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Hirai F, Yamaguchi M, <u>Seto T</u> , Takenoyama M, Ichinose Y	Cystic brain metastasis of non-small-cell lung cancer successfully controlled with Ommaya reservoir placement	Int Canc Conf J	2(2)	89-92	2013
Niho S, <u>Yamanaka T</u> , Umemura S, Matsumoto S, Yoh K, <u>Goto</u> <u>K</u> , Ohmatsu H, Ohe Y.	Renal Toxicity Caused by Brand-name Versus Generic Cisplatin: A Comparative Analysis.	Japanese Journal of Clinical Oncolgy	OXFORD UNIVERSITY PRESS	390-395	2013

<p>Kawahara M, Atagi S, Komuta K, <u>Yoshioka H</u>, Kawasaki M, Fujita Y, Yonei T, Ogushi F, Kubota K, Nogami N, Tsuchiya M, Shibata K, Tomizawa Y, Minato K, Fukuoka K, Asami K, <u>Yamanaka T.</u></p>	<p>Carboplatin plus Either Docetaxel or Paclitaxel for Japanese Patients with Advanced Non-small Cell Lung Cancer.</p>	<p>Anticancer Reserch</p>	<p>The International Institute of Anticancer Research</p>	<p>4631-4637</p>	<p>2013</p>
<p>Misumi Y, Nishio M, <u>Takahashi T</u>, Ohyanagi F, Horiike A, Murakami H, Kenmotsu H, <u>Yamamoto N</u>, Ishii M, Shimokawa T, Hida N, Okamoto H.</p>	<p>A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer</p>	<p>Jpn J Clin Oncol.</p>	<p>44(2)</p>	<p>116-121.</p>	<p>2014</p>

<p>Kogure Y, Ando M, <u>Saka H</u>, Chiba Y, <u>Yamamoto N</u>, Asami K, Hirashima T, <u>Seto T</u>, Nagase S, Otsuka K, Yanagihara K, <u>Takeda K</u>, Okamoto I, Aoki T, <u>Takayama K</u>, Yamasaki M, Kudoh S, Katakami N, Miyazaki M, Nakagawa K.</p>	<p>Histology and Smoking Status Predict Survival of Patients with Advanced Non-Small-Cell Lung Cancer:: Results of West Japan Oncology Group (WJOG) Study 3906L.</p>	<p>J Thorac Oncol</p>	<p>8(6)</p>	<p>753-8</p>	<p>2013</p>
<p>Kawaguchi T, Ando M, Ito N, Isa S, Tamiya A, Shimizu S, <u>Saka H</u>, Kubo A, Koh Y, Matsumura A.</p>	<p>Rationale and design of the japan molecular epidemiology for lung cancer study.</p>	<p>Lung Cancer</p>	<p>14(5)</p>	<p>596-600</p>	<p>2013</p>

<p>Taniyama TK, <u>Nokihara H</u>, Tsuta K, Horinouchi H, Kanda S, Fujiwara Y, <u>Yamamoto N</u>, Koizumi F, Yunokawa M, Tamura T.</p>	<p>Clinicopathological Features in Young Patients Treated for Small-Cell Lung Cancer: Significance of Immunohistological and Molecular Analyses.</p>	<p>Clin Lung Cancer</p>	<p>15(3)</p>	<p>244-7</p>	<p>2013</p>
<p>Harada T, <u>Oizumi S</u>, Ito K, Takamura K, Kikuchi E, Kuda T, Sugawara S, Suzuki A, Maemondo M, Fujita Y, Kinoshita I, <u>Inoue A</u>, Hommura F, Katsuura Y, Dosaka-Akita H, Isobe H, Nishimura M.</p>	<p>A Phase II Study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901.</p>	<p>Oncologist</p>	<p>18(4)</p>	<p>439-45</p>	<p>2013</p>

<p>Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Saijo Y, Hagiwara K, Morita S, and Nukiwa T, for the North-East Japan Study Group.</p>	<p>Updated Overall Survival Results from A Randomized Phase III Trial Comparing Gefitinib with Carboplatin-Paclitaxel for Chemo-Naïve Non-Small Cell Lung Cancer with Sensitive EGFR Gene Mutations (NEJ002).</p>	<p>Ann Oncol</p>	<p>24(1)</p>	<p>Sep-54</p>	<p>2013</p>
---	---	------------------	--------------	---------------	-------------

<p>Yuki Misumi, <u>Makoto</u> <u>Nishio</u>, <u>Toshiaki</u> <u>Takahashi</u>, Fumiyoshi Ohyanagi, Atsushi Horiike, Haruyasu Murakami, Hirotsugu Kenmotsu, <u>Nobuyuki</u> <u>Yamamoto</u>, Mari Ishii, Tsuneo Shimokawa, Naoya Hida, Hiroaki Okamoto</p>	<p>A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer</p>	<p>Japanese Journal of Clinical Oncology</p>	<p>44(2)</p>	<p>116-121</p>	<p>2014</p>
---	--	---	--------------	----------------	-------------

<p>Takaaki Tokito, Hirotsugu Kenmotsu, Reiko Watanabe, Ichiro Ito, Takehito Shukuya, Akira Ono, Yukiko Nakamura, Asuka Tsuya, Tateaki Naito, Haruyasu Murakami, <u>Toshiaki</u> <u>Takahashi</u>, Yasuhisa Ohde, Haruhiko Kondo, Masahiro Endo, Toru Kameya, Takashi Nakajima, Keita Mori, _</p>	<p>Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens</p>	<p>International Journal of Clinical Oncology</p>	<p>19(1)</p>	<p>63-67</p>	<p>2014</p>
--	--	---	--------------	--------------	-------------

<u>Nobuyuki</u> <u>Yamamoto</u>					
Kazushige Wakuda, Hirotsugu Kenmotsu, Masakuni Serizawa, Yasuhiro Koh, Mitsuhiro Isaka, Shoji Takahashi, Akira Ono, Tetsuhiko Taira, Tateaki Naito, Haruyasu Murakami, Keita Mori, Masahiro	Molecular profiling of small cell lung cancer in a Japanese cohort	Lung Cancer	84(2)	139-144	2014

<p>Endo, Takashi Nakajima, Yasuhisa Ohde, <u>Toshiaki</u> <u>Takahashi</u>, <u>Nobuyuki</u> Yamamoto</p>					
<p>Hisao Imai, Keita Mori, Kazushige Wakuda, Akira Ono, <u>Hiroaki</u> <u>Akamatsu</u>, Takehito Shukuya, Tetsuhiko Taira, Hirotugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro</p>	<p>Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer</p>	<p>Annals of Thoracic Medicine</p>	<p>10(1)</p>	<p>61-66</p>	<p>2015</p>

Endo, Takashi Nakajima, <u>Nobuyuki</u> Yamamoto, <u>Toshiaki</u> <u>Takahashi</u>					
Takenaka T, Takenoyama M, Inamasu E, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, <u>Seto T</u> , Ichinose Y	Role of surgical resection for patients with limited disease-small cell lung cancer	Lung Cancer	88(1)	52-56	2015
Naito T, <u>Seto T</u> , <u>Takeda K</u> , <u>Goto K</u> , Okamoto I, Nakagawa K, Ohba T, Murakami H, <u>Takahashi T</u> , <u>Yamanaka T</u> ,	Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer.	Lung Cancer	Elsevier	339-343	2014

<p><u>Yamamoto N.</u></p>					
<p><u>Seto T</u>, <u>Kato T</u>, <u>Nishio M</u>, <u>Goto K</u>, <u>Atagi S</u>, <u>Hosomi Y</u>, <u>Yamamoto N</u>, <u>Hida T</u>, <u>Maemondo M</u>, <u>Nakagawa K</u>, <u>Nagase S</u>, <u>Okamoto I</u>, <u>Yamanaka T</u>, <u>Tajima K</u>, <u>Harada R</u>, <u>Fukuoka M</u>, <u>Yamamoto N.</u></p>	<p>Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (J025567): an open-label, randomised, multicentre, phase 2 study.</p>	<p>The Lancet Oncology</p>	<p>Elsevier</p>	<p>1236-1244</p>	<p>2014</p>

<p>Murakami H, <u>Yamanaka T</u>, <u>Seto T</u>, Sugio K, Okamoto I, <u>Sawa T</u>, Hirashima T, <u>Takeda K</u>, Atagi S, Fukuoka M, Nakanishi Y, Nakagawa K, <u>Yamamoto N</u>.</p>	<p>A Phase II Study of Zoledronic Acid Combined with Docetaxel for Non-small-cell Lung Cancer: West Japan Oncology Group.</p>	<p>cancer Science</p>	<p>Wiley</p>	<p>989-995</p>	<p>2014</p>
<p>Wakuda K, Kenmotsu H, Serizawa M, Koh Y, Isaka M, Takahashi S, Ono A, Taira T, Naito T, Murakami H, Mori K, Endo M, Nakajima T, Ohde Y, <u>Takahashi T</u>, <u>Yamamoto N</u>.</p>	<p>Molecular profiling of small cell lung cancer in a Japanese cohort.</p>	<p>Lung Cancer.</p>	<p>84(2)</p>	<p>139-144</p>	<p>2014</p>

<p>Watanabe M, Serizawa M, Sawada T, <u>Takeda K</u>, <u>Takahashi T</u>, <u>Yamamoto N</u>, Koizumi F, Koh Y.</p>	<p>A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood.</p>	<p>J Transl Med.</p>	<p>12</p>	<p>doi :10.1186/1479-5876-12-143(open access)</p>	<p>2014</p>
<p>Wakuda K, Kenmotsu H, Naito T, <u>Akamatsu H</u>, Ono A, Shukuya T, Nakamura Y, Tsuya A, Murakami H, <u>Takahashi T</u>, Endo M, Nakajima T, <u>Yamamoto N</u>.</p>	<p>Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.</p>	<p>Am J Clin Oncol</p>	<p>38(1)</p>	<p>28-32</p>	<p>2015</p>

<p>Imai H, Mori K, Wakuda K, Ono A, <u>Akamatsu H</u>, Shukuya T, Taira T, Kenmotsu H, Naito T, Kaira K, Murakami H, Endo M, Nakajima T, <u>Yamamoto N</u>, <u>Takahashi T</u>.</p>	<p>Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer.</p>	<p>Ann Thorac Med</p>	<p>10(1)</p>	<p>61-66</p>	<p>2015</p>
<p>Oki M, Yatabe Y, <u>Saka H</u>, Kitagawa C, Kogure Y, Ichihara S, Moritani S.</p>	<p>Feasibility and accuracy of molecular testing in specimens obtained with small biopsy forceps: comparison with the results of surgical specimens.</p>	<p>Respiration.</p>	<p>89(3)</p>	<p>235-42</p>	<p>2015</p>

<p>Abe T, Takada K, Ohe Y, Kudoh S, Ichinose Y, Ikamoto H, <u>Yamamoto N</u>, <u>Yoshioka H</u>, Minato K, <u>Sawa T</u>, Iwamoto Y, <u>Saka H</u>, Mizusawa J, Shibata T, Nakamura S, Ando M, Yokoyama A, Nakagawa K, Saijo N, Tamura T.</p>	<p>Randomized Phase III Trial Comparing Weekly Docetaxe I Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L.</p>	<p>J Clin Oncol.</p>	<p>33(6)</p>	<p>575-81</p>	<p>2015</p>
<p>Kawano Y, Okamoto I, Fukuda H, Ohe Y, Nakamura S, Nakagawa K, Hotta K, Kiura K, Takiguchi Y, <u>Saka H</u>, Okamoto H,</p>	<p>Current status and future perspectives of cooperative study groups for lung cancer in japan.</p>	<p>Respiratory Investigation.</p>	<p>52(6)</p>	<p>339-47</p>	<p>2014</p>

<p>Takayama K, Semba H, Kobayashi K, Kenmotsu H, Tsuboi M, Yamamoto N, Nukiwa T, Nakanishi Y.</p>					
<p>Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H, Ibata H, Kozuki T, Endo T, Tamura A, Kamimura M, Sakamoto K, Yoshimi M, Soejima Y, Tomizawa Y, Isa S, Takada M, <u>Saka H.</u></p>	<p>Randomized phase III trial of erlotinib versus docetaxel as second - or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and erlotinib lung cancer trial (DELTA).</p>	<p>J Clin Oncol</p>	<p>32(18)</p>	<p>Aug-02</p>	<p>2014</p>

<p>Mizugaki H, Fujiwara Y, <u>Yamamoto N</u>, Yagishita S, Kitazono S, Tanaka A, Horinouchi H, Kanda S, <u>Nokihara H</u>, Tsuta K, Asamura H, Tamura T</p>	<p>Adjuvant Chemotherapy in Patients with Completely Resected Small Cell Lung Cancer: A Retrospective Analysis of 26 Consecutive Cases</p>	<p>Jpn J Clin Oncol</p>	<p>44(9)</p>	<p>835-840</p>	<p>2014</p>
<p>Yokouchi H, Kanazawa K, Ishida T, <u>Oizumi S</u>, Shinagawa N, Sukoh N, Harada M, Ogura S, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M.</p>	<p>Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.</p>	<p>Mol Clin Oncol.</p>	<p>2(5)</p>	<p>744-750</p>	<p>2014</p>

<p>Kawashima Y, <u>Inoue A</u>, Sugawara S, <u>Oizumi S</u>, Maemondo M, Okudera K, Suzuki T, Usui K, Harada M, Morikawa N, Hasegawa Y, Saito R, Ishimoto O, Sakakibara T, Asahina H, Nukiwa T.</p>	<p>Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802.</p>	<p>Respir Investig.</p>	<p>52(3)</p>	<p>190-4</p>	<p>2014</p>
<p>Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, <u>Harada T</u>, Harada M, Takamura K, <u>Oizumi S</u>, Kinoshita I, Katsuura Y, Honjo O,</p>	<p>Phase II Trial of Carboplatin and Pemetrexed as First-Line Chemotherapy for Non-Squamous Non-Small Cell Lung Cancer, and Correlation Between the Efficacy/Toxicity and Genetic Polymorphisms Associated with Pemetrexed Metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.</p>	<p>Cancer Chemother Pharmacol</p>	<p>74(6)</p>	<p>1149-57</p>	<p>2014</p>

<p>Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M.</p>					
<p>赤松弘朗、山 本信之</p>	<p>小細胞肺癌に対する予防的全脳 照射</p>	<p>腫瘍内科</p>	<p>13(1)</p>	<p>91-95</p>	<p>2014</p>
<p>赤松弘朗、山 本信之</p>	<p>Learn more from previous clinical trial. Clinical Trials. Gov number: NCT00016211</p>	<p>PCI 試験今昔 . がん分子標的治</p>	<p>12(3)</p>	<p>101-102</p>	<p>2014</p>

発表

<p><u>Seto T,</u> <u>Takahashi T,</u> <u>Yamanaka T,</u> <u>Harada H,</u> <u>Nokihara H,</u> <u>Saka H,</u> <u>Nishio M,</u> Nakagawa K, Takayama K, Ishimoto O, <u>Takeda K,</u> <u>Yoshioka H,</u> Tachihara M, Sakai H, <u>Goto</u> <u>K, Yamamoto N</u></p>	<p>Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial</p>	<p>J Clin Oncol</p>	<p>32:5s</p>	<p>(suppl; abstr 7503)</p>	<p>2014</p>
---	---	---------------------	--------------	----------------------------	-------------